These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 24412276)
1. The cystic fibrosis V232D mutation inhibits CFTR maturation by disrupting a hydrophobic pocket rather than formation of aberrant interhelical hydrogen bonds. Loo TW; Clarke DM Biochem Pharmacol; 2014 Mar; 88(1):46-57. PubMed ID: 24412276 [TBL] [Abstract][Full Text] [Related]
2. Positional dependence of non-native polar mutations on folding of CFTR helical hairpins. Wehbi H; Gasmi-Seabrook G; Choi MY; Deber CM Biochim Biophys Acta; 2008 Jan; 1778(1):79-87. PubMed ID: 17949679 [TBL] [Abstract][Full Text] [Related]
3. Corrector VX-809 stabilizes the first transmembrane domain of CFTR. Loo TW; Bartlett MC; Clarke DM Biochem Pharmacol; 2013 Sep; 86(5):612-9. PubMed ID: 23835419 [TBL] [Abstract][Full Text] [Related]
4. Non-native interhelical hydrogen bonds in the cystic fibrosis transmembrane conductance regulator domain modulated by polar mutations. Choi MY; Cardarelli L; Therien AG; Deber CM Biochemistry; 2004 Jun; 43(25):8077-83. PubMed ID: 15209503 [TBL] [Abstract][Full Text] [Related]
5. Correctors promote folding of the CFTR in the endoplasmic reticulum. Loo TW; Bartlett MC; Clarke DM Biochem J; 2008 Jul; 413(1):29-36. PubMed ID: 18361776 [TBL] [Abstract][Full Text] [Related]
6. Interhelical hydrogen bonds in the CFTR membrane domain. Therien AG; Grant FE; Deber CM Nat Struct Biol; 2001 Jul; 8(7):597-601. PubMed ID: 11427889 [TBL] [Abstract][Full Text] [Related]
7. CFTR transmembrane segments are impaired in their conformational adaptability by a pathogenic loop mutation and dynamically stabilized by Lumacaftor. Krainer G; Schenkel M; Hartmann A; Ravamehr-Lake D; Deber CM; Schlierf M J Biol Chem; 2020 Feb; 295(7):1985-1991. PubMed ID: 31882543 [TBL] [Abstract][Full Text] [Related]
8. Repair of CFTR folding defects with correctors that function as pharmacological chaperones. Loo TW; Clarke DM Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776 [TBL] [Abstract][Full Text] [Related]
9. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors. Amico G; Brandas C; Moran O; Baroni D Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989 [TBL] [Abstract][Full Text] [Related]
10. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. Wang Y; Loo TW; Bartlett MC; Clarke DM J Biol Chem; 2007 Nov; 282(46):33247-33251. PubMed ID: 17911111 [TBL] [Abstract][Full Text] [Related]
11. The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. Chen EY; Bartlett MC; Loo TW; Clarke DM J Biol Chem; 2004 Sep; 279(38):39620-7. PubMed ID: 15272010 [TBL] [Abstract][Full Text] [Related]
12. Polar residues in membrane domains of proteins: molecular basis for helix-helix association in a mutant CFTR transmembrane segment. Partridge AW; Melnyk RA; Deber CM Biochemistry; 2002 Mar; 41(11):3647-53. PubMed ID: 11888281 [TBL] [Abstract][Full Text] [Related]
13. Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry. Sinha C; Zhang W; Moon CS; Actis M; Yarlagadda S; Arora K; Woodroofe K; Clancy JP; Lin S; Ziady AG; Frizzell R; Fujii N; Naren AP Chembiochem; 2015 Sep; 16(14):2017-22. PubMed ID: 26227551 [TBL] [Abstract][Full Text] [Related]
14. Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments. Loo TW; Bartlett MC; Clarke DM J Biol Chem; 2002 Aug; 277(31):27585-8. PubMed ID: 12070134 [TBL] [Abstract][Full Text] [Related]
16. VX-809 and related corrector compounds exhibit secondary activity stabilizing active F508del-CFTR after its partial rescue to the cell surface. Eckford PD; Ramjeesingh M; Molinski S; Pasyk S; Dekkers JF; Li C; Ahmadi S; Ip W; Chung TE; Du K; Yeger H; Beekman J; Gonska T; Bear CE Chem Biol; 2014 May; 21(5):666-78. PubMed ID: 24726831 [TBL] [Abstract][Full Text] [Related]
17. Corrector VX-809 promotes interactions between cytoplasmic loop one and the first nucleotide-binding domain of CFTR. Loo TW; Clarke DM Biochem Pharmacol; 2017 Jul; 136():24-31. PubMed ID: 28366727 [TBL] [Abstract][Full Text] [Related]
18. Corrector-mediated rescue of misprocessed CFTR mutants can be reduced by the P-glycoprotein drug pump. Loo TW; Bartlett MC; Shi L; Clarke DM Biochem Pharmacol; 2012 Feb; 83(3):345-54. PubMed ID: 22138447 [TBL] [Abstract][Full Text] [Related]
19. Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. Phuan PW; Veit G; Tan J; Roldan A; Finkbeiner WE; Lukacs GL; Verkman AS Mol Pharmacol; 2014 Jul; 86(1):42-51. PubMed ID: 24737137 [TBL] [Abstract][Full Text] [Related]
20. Elexacaftor/VX-445-mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics. Kim M; McDonald EF; Sabusap CMP; Timalsina B; Joshi D; Hong JS; Rab A; Sorscher EJ; Plate L J Biol Chem; 2023 Oct; 299(10):105242. PubMed ID: 37690692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]